Interleukin-2 receptor monoclonal antibodies in renal transplantation: Meta-analysis of randomised trials

British Medical Journal

Volumn 326, Issue 7393, 2003, Pages 789-791

  Adu, Dwomoa ^a   Cockwell, Paul ^a   Ives, Natalie J ^b   Shaw, Jonathan ^a   Wheatley, Keith ^b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN A; DACLIZUMAB; INOLIMOMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ARTICLE; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DEATH; GRAFT INFECTION; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CANCER; KIDNEY TRANSPLANTATION; LYMPHOMA; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTIBODIES, MONOCLONAL; CYCLOSPORINE; DRUG THERAPY, COMBINATION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, INTERLEUKIN-2; TREATMENT OUTCOME;

EID: 0037433703     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. UK Transplant website. www.uktransplant.org (accessed 25 February 2003).
2. Hariharan S, Johnson C, Bresnahan B, Taranto S, McIntosh M, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000;342:605-12.
3. Matas A, Gillingham K, Payne W, Najarian J. The impact of an acute rejection episode on long-term renal allograft survival. Transplantation 1994;57:857-9.
4. Kamel O, van de Rijn M, Lebrun D, Weiss L, Warnke R, Dorfman R. A multivariate analysis of discharge immunosuppression and posttransplant malignancy. Am J Transplant 2001;1(suppl 1):353.
5. Jamil B, Nicholls K, Becker G, Walker R. Impact of acute rejection therapy on infections and malignancies in renal transplant recipients. Transplantation 1999;68:1597-619.
6. Morgan D, Ruscettis F, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrow. Science 1976;193:1007-8.
7. Robb R, Greene W, Rusk C. Low and high affinity cellular receptors for interleukin 2: implications for the level of Tac antigen. J Exp Med 1984;162:358-62.
8. Kirkman R, Barrett L, Carpenter C, McKay DB, Milford EL, Ramos EL, et al. A randomised trial of anti-Tac monoclonal antibody in human renal transplantation. Transplantation 1991;51:107-13.
9. Van Gelder T, Zietse R, Mulder A, Yzermans JNM, Hesse CJ, Vaessen LMB, et al. A double blind, placebo-controlled study of monoclonal antiinterleukin-2 receptor antibody (BT563) administration to prevent acute rejection after kidney transplantation. Transplantation 1995;60:248-52.
10. Knoll G, Bell R. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. BMJ 1999;318:1104-7.